Almitrine as a non ventilatory strategy to improve intrapulmonary shunt in COVID-19 patients

Running title: almitrine and COVID-19 related hypoxemia

Losser MR, MD, PhD\textsuperscript{1,2}; Lapoix C, Resident\textsuperscript{1}, Champigneulle B, MD\textsuperscript{3}; Delannoy M, MD\textsuperscript{1}; Payen JF, MD, PhD\textsuperscript{3,4}, Payen D, MD, PhD\textsuperscript{6}

Institutions

\textsuperscript{1} CHRU Nancy, Département d’Anesthésie Réanimation Brabois Adulte, Rue du Morvan, 54511 Vandoeuvre-les-Nancy, France
\textsuperscript{2} Inserm UMR 1116, Equipe 2, Faculté de Médecine, Université de Lorraine, 9 Avenue de la Forêt de Haye - CS 50184, 54505 Vandoeuvre-les-Nancy Cedex, France
\textsuperscript{3} Pôle Anesthésie Réanimation, CHU Grenoble Alpes, F-38000, Grenoble, France
\textsuperscript{4} Univ. Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, GIN, 38000 Grenoble, France
\textsuperscript{5} UMR Inserm 1160, UFR de Médecine de l’Université Paris 7, Paris, France

\textit{e-mails}

Marie Reine Losser : mr.losser@chru-nancy.fr;

Coline Lapoix : coline.lapoix@laposte.net

Benoit Champigneulle: bchampigneulle@chu-grenoble.fr

Matthieu Delannoy: m.delannoy@chru-nancy.fr

Jean-Francois Payen : jfpayen@univ-grenoble-alpes.fr

Didier Payen: dpayen1234@orange.fr
key words: Hypoxic pulmonary vasoconstriction, prone position, intra-pulmonary shunt, SARS-CoV-2

Acknowledgements: We thank Doctors Marie Dominique Fratacci and Valérie Girard (Servier Laboratory, Courbevoie, France) for their permanent support and facilitation. We thank Drs Béatrice Demoré and Nathalie Commun from Pharmacie CHRU Nancy for permanent support.

Major findings

During COVID-19, pulmonary blood vessel dilatation induces a severe intrapulmonary oxygen shunt. Almitrine iv infusion was associated with a rapid and significant improvement of PaO2 in mechanically ventilated patients during both prone or supine positioning.
Abstract: In severe COVID-19 pulmonary failure, hypoxia is mainly related to pulmonary vasodilation with altered hypoxic pulmonary vasoconstriction (HPV). Besides prone positioning, other non-ventilatory strategies may reduce the intrapulmonary shunt. This study has investigated almitrine, a pharmacological option to improve oxygenation.

Patients and Method. A case control series of 17 confirmed COVID-19 mechanically ventilated patients in prone or supine positioning was collected: 10 patients received two doses of almitrine (4 and 12 mcg/kg/min) at 30-45 min interval each, and were compared to 7 “control” COVID-matched patients conventionally treated. The end-point was the reduction of intrapulmonary shunt increasing the PaO₂ and ScvO₂.

Results Patients were male (59%) with median (25th, 75th percentiles) age of 70 (54-78) years and a BMI of 29 (23-34). At stable mechanical ventilatory settings, PaO₂ (mmHg) at FiO₂ 1 (135 (85, 195) to 214 (121, 275); p = 0.06) tended to increase with almitrine. This difference was significant when the best PaO₂ between the 2 doses was used: 215 (123,294) vs baseline (p = 0.01). A concomitant increase in ScvO₂ occurred ((73 (72, 76) to 82 (80, 87); p = 0.02). Eight over 10 almitrine-treated patients increased their PaO₂, with no clear dose-effect. During the same time, the controls did not change PaO₂.

In conclusion, in early COVID-19 with severe hypoxemia, almitrine infusion is associated with improved oxygenation in prone or supine positioning. This pharmacological intervention may offer an alternative and/or an additional effect to proning and might delay or avoid more demanding modalities such as ECMO.
Introduction

The clinical presentation of COVID-19 disease is heterogenous, ranging from no symptoms to severe acute respiratory failure (ARF), which may have a poor prognosis. (1, 2) The lung contamination by SARS-CoV-2 is typically characterized by a major difficulty to oxygenate the arterial blood. (3) This severe hypoxemia is associated with preserved respiratory mechanical properties, in particular the pulmonary system compliance. As recently quoted by Gattinoni et al(4), the COVID-19 pneumonia seems to have 2 different phenotypes: the early phase, with severe hypoxemia and close to normal respiratory mechanics with a moderate effect of PEEP on lung recruitment; the later phase, corresponding to the more “classic” ARDS alteration of respiratory mechanics such as a reduced compliance with chest CT Scan images of diffuse ground-glass opacities and condensations. The hypoxia during the early phase seems to mainly result from an important ventilation/perfusion (VA/Q) mismatch(5) associated with an altered pulmonary vasoconstriction. The “protective” mechanism called hypoxic pulmonary vasoconstriction (HPV) normally reduces the blood flow in poorly or non-ventilated areas towards aerated zones leading to reduce the (VA/Q) mismatch. HPV seems poorly functional in COVID-19 severe patients in absence of “cor pulmonale”.(2)

Most of the publications on severe COVID-19 describe intubated and mechanically ventilated patients, installed in prone positioning as an adjuvant therapy to limit hypoxia. The prone positioning in ARDS is supposed to facilitate alveolar recruitment, and to decrease the heterogeneity of compliance.(6) In theory, this modality should have a limited effect during the COVID-19 early phase. The recent publications demonstrated that the majority of patients improved PaO2 after prone positioning,(7) which suggests another mechanism to improve PaO2.
The most probable was a pulmonary blood flow redistribution towards the ventilated areas by gravitational forces. This modality creates a huge work load to the care team, and increases the risk of endotracheal tube obstruction and malposition, and pressure sores on face and chest.(6)

In the 90s’, other non-ventilatory strategies have been reported including inhaled nitric oxide(8), almitrine bismesylate (9, 10) or a combination of both.(11) According to the French National agency for Drug Security (ANSM), only iv almitrine was indicated for hypoxic acute respiratory failure as Drug of Major Therapeutic Interest. The brutal COVID-19 outbreak with many severe hypoxic patients prompted intensivists to test iv almitrine to improve HPV(12, 13) and to reduce the intrapulmonary shunt. The use of ECMO is limited to trained centres, which could not meet COVID-19-related demands. We hypothesized that almitrine might restore even partially a HPV response, both in supine or prone positioning.

We investigated 10 COVID-19 patients mechanically ventilated at FiO₂ 1 with a severe intrapulmonary shunt during their early phase. The emergency conditions and the acute high inflow of patients to ICU impeded the design of a randomized control trial. To eliminate the eventuality of a spontaneous evolution of hypoxia, these patients were compared with 7 control-matched COVID-19 patients treated conventionally.

Patients and measurements

The Research Program database of the Departement d’Anesthésie- Reanimation Brabois Adulte was submitted to the “Direction de la Recherche et Innovation (ref 2020PI080)”, and was agreed by the research Ethical Committee (Saisine 263) of Centre Hospitalier Régional Universitaire (CHRU) de Nancy, France. The relatives or patients were questioned about
objections to use almitrine and collected data for scientific purposes and/or potential publications or not. The statement including also the opposition forms was dated and recorded in medical file. The study was retrospectively registered at ClinicalTrials.gov after enrolment (NCT04380727, Principal Investigator: Marie-Reine LOSSER, M.D., Ph.D., May 7, 2020).

Between March 16 and April 12, 2020, COVID-19 patients referred to ICU were screened to receive iv almitrine using the following criteria: a positive RT-PCR, a highly suggestive thoracic CTScan, and a severe hypoxemia leading to intubation for less than 3 days. The exclusion criteria were: the presence of an acute cor pulmonale on the trans-thoracic 2D Echo-Doppler and abnormal liver function tests or hyperlactatemia. Ten successive patients were studied according to the following protocol: baseline measurement in prone or supine positioning; second measurement 30 to 45 min after 4 mcg/kg/min iv almitrine bismesylate (Vectarion®, Servier Laboratory, Neuilly, France), and a third measurement 30-45 min after 12 mcg/kg/min infusion rate. Because of a shortage of drug store at national level, a protocol using continuous infusion was not considered.

The recorded parameters were: the ventilatory settings unchanged along the protocol, including FiO2, PEEP level, tidal volume (VT), peak inspiratory pressure, plateau pressure; haemoglobin concentration, blood gases simultaneously sampled on the arterial catheter and on the central catheter to assess central venous oxygen saturation ScvO2, and arterial lactate, right atrial pressure; cardiac output when possible (Mostcare®, Vygon, Ecouen, France). Similar data were collected on a matched control group of COVID-19 patients, matched on gender, age, BMI and duration of mechanical ventilation, with serial measurements corresponding to the duration of almitrine testing. Data were reported according to the Strobe Statement for case control studies.
Statistical analysis

Data were reported as median (25th-75th percentiles) for continuous variables and as count (percentage) for categorical variables. Change in blood gases parameters during almitrine infusion were first assessed using a Friedman test followed by a pairwise Wilcoxon signed-ranks post-hoc test with Bonferroni correction when appropriate. Second, to perform a two-points comparison (i.e. baseline and after almitrine infusion) with the control group (baseline and H8 measurement), we only considered the best variation in term of PaO2 regardless of the infusion dose of almitrine (4 or 12 mcg/kg/min). In the two groups, difference between before (baseline) and after (almitrine infusion or H8) measurement was assessed using a Wilcoxon signed-ranks test. All tests were 2-sided and a p value <0.05 was considered as statistically significant. Statistical analyses were performed using R version 3.6.0 for Mac OS (The R Foundation for Statistical Computing, Vienna, Austria).

Results

All patients had a confirmed diagnosis of COVID-19 (positive PCR testing). The median age was 70 (54-78) years, with 10/17 males, having a median BMI of 29 (23-34). Haemoglobin was stable at 12.2 (8.9-13.8) g/dL. Most of the patients were intubated just before or soon after ICU admission. Patients from both groups had co-morbidities, mostly metabolic and/or cardiovascular diseases under chronic treatment (Table 1). At the time of manuscript submission, in almitrine group 2 patients died and 6 patients were extubated and discharged from the ICU, the remaining being still mechanically ventilated. In the control group, 2 died and 5 were extubated and discharged from the ICU.
Table 2 shows the hemodynamic, gas exchange and mechanical ventilation parameters from baseline, 4 and 12 mcg/kg/min of almitrine infusion. PaO₂ tended to increase (p = 0.06) with a significant increase in ScvO₂ (p =0.03). All other parameters did not change during the protocol. The changes in PaO₂ did not parallel the increasing doses of almitrine (data not shown). In the control COVID group, none of the collected parameters changed after 8hrs (Supplementary table S1). The whiskers box plot of Figure 1 shows the median PaO₂/FiO₂ for almitrine and control groups. The best response in PaO₂ increase starting from baseline was found significant only in the almitrine-treated group (p = 0.01), while it remained stable in controls. Figure 2 shows the individual data for both PaO₂ and ScvO₂ in both groups, which significantly increased only in the almitrine group. Eight over 10 patients increased their PaO₂ with almitrine, with no clear relation with the level of infusion rate. Of note, when the drug was available to continue, the increase in PaO₂ associated with almitrine infusion persisted (3 patients), which permitted to reduce the number of positioning changes. During this short perfusion time no hemodynamic side effects were observed and lactate remained stable (<1.5 mmol/L) (data not shown).
Discussion

Intravenous almitrine was associated with almost a doubling of the PaO₂/FiO₂ ratio in the early phase of severe COVID-19 ARDS with no clear dose-effect relation. SvcO₂ increased consistently, while neither Pra nor CI was altered. The individual responses related to almitrine infusion varied in amplitude between patients (fig2A), but 8 over 10 patients responded in term of PaO₂ with an average of 80 mmHg increase from baseline to the most efficient dose of almitrine.

In our experience, the patients admitted in ICU with a PaO₂/FiO₂ lower than 100 mmHg required a rescue intubation and mechanical ventilation at FiO₂ close to 1. Standard ventilatory settings were used as previously reported in COVID-19(3), including moderate PEEP with a VT close to 6 ml/kg IBW. Among the non-ventilatory method to improve oxygenation, the prone positioning is leading with frequent and rapid increase in PaO₂/FiO₂.(6) As recently stated by ATS(6), prone positioning improves oxygenation mainly through respiratory mechanics improvement, limiting the heterogeneity of the gas volume partition. The apparent benefit of prone positioning on PaO₂ in “early” COVID-19 with almost normal respiratory mechanics(18) strongly suggests that prone positioning improves hypoxia and reduces the intra-pulmonary VA/Q mismatch by another mechanism.

The absence of cor pulmonale despite severe ARF in COVID-19 indicates a relative dilatation of the pulmonary vascular bed with a “normal” pulmonary blood flow.(19) The logical hypothesis was that the prone positioning is changing the partition of pulmonary blood flow towards better ventilated areas by gravitation. The severe VA/Q mismatch in COVID-19 associated with pulmonary vasodilation indicates an alteration in HPV.(5) Years ago, we and
others have shown that almitrine may spectacularly improve PaO₂ by reducing the intra-pulmonary oxygen shunt.\((5, 13)\) In the present pilot study, almitrine was used as a test to restore, even though partially, the HPV in supine or prone positioning (Fig 2B). The combination of these conditions (prone and almitrine) could then be seen as a combination of gravitational and pharmacological effects to improve the oxygen VA/Q mismatch. The observed increase in P/F ratio in 80% of the patients confirmed this approach. The small cohort of patients does not allow concluding about any additional effect of these therapies. Worthy of note, in 3 patients the re-positioning from prone to supine under almitrine prevented the loss of the benefit of prone positioning on PaO₂ values. The observed results with almitrine would not be related to the spontaneous evolution of the patients as suggested by the stable PaO₂ in the control COVID-19.

The PaO₂ increase associated with almitrine infusion was concomitant with a significant increase in ScvO₂. This observation confirms the absence of tissue hypoperfusion with no large peripheral O₂ extraction, as suggested by the low lactate levels. This ScvO₂ increase provides a greater reserve for O₂ extraction in case of acute desaturation, and increased the level of dissolved O₂, the diffusible form of oxygen to the tissues.\(^{(20)}\)

This case control series has several limitations in addition to the small size cohort (17 patients). First, although the “control” COVID-19 patients were selected on stringent criteria to match the studied group, it was not randomized and could be biased. The stability in PaO₂ during 8 hours reinforced the credence in an almitrine effect. In absence of a drug shortage, all of these patients would have received almitrine. This shortage resulted from the small national stock of almitrine facing an important demand during the pandemic. Second, although the data were prospectively collected, the overwhelmed care team capabilities in a dramatic context explains why some data were missing. Third, for the same reason, we were not able to administer the drug
for a longer period than 36 to 48 hours for few patients. This precludes any conclusion about the
potential benefit on mechanical ventilation duration and on the number of prone positioning.
Following the same line of thinking, the almitrine test on arterial oxygenation cannot be proposed
as either a prognostic test or a predictor of the prone position response.

In conclusion, in a case series of early hypoxemic COVID-19 pneumonia with acute
respiratory failure, iv almitrine was associated with an improvement in arterial blood oxygenation
both in prone or supine positioning in most of the patients, suggesting a partial recovery of the
pulmonary vessels’ contractility. This pharmacological intervention may offer an alternative
and/or an additional strategy to the prone positioning in severe COVID-19 ARDS. It may help to
support the lung function when ECMO possibilities are very limited.
References


<table>
<thead>
<tr>
<th>Patient</th>
<th>BMI</th>
<th>Past medical history</th>
<th>Medications</th>
<th>Delay for almitrine administration after intubation</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>27</td>
<td>A Fib – SAS</td>
<td>Proton pump inhibitor Anti histaminic</td>
<td>D3</td>
<td>Dead D17 Limitation of care</td>
</tr>
<tr>
<td>2</td>
<td>26</td>
<td>Ischemic heart disease – NIDD – prostate cancer</td>
<td>Aspirine Calcium channel blocker Fibrate/statins ACE inhibitors Proton pump inhibitor Beta blocker Benzodiazepine</td>
<td>D0</td>
<td>Extubation D5 ICU discharge D19</td>
</tr>
<tr>
<td>3</td>
<td>31</td>
<td>Hypertension – NIDD</td>
<td></td>
<td>D4</td>
<td>Extubation D6 ICU Discharge D7</td>
</tr>
<tr>
<td>4</td>
<td>29</td>
<td>DVT – pulmonary and urinary tuberculosis</td>
<td>Oral anticoagulant</td>
<td>D1</td>
<td>Extubation D3 Discharged home D8</td>
</tr>
<tr>
<td>5</td>
<td>35</td>
<td>A Fib – Hypertension – NIDD - Transient stroke</td>
<td></td>
<td>D1</td>
<td>Extubation D11 ICU discharge D15</td>
</tr>
<tr>
<td>6</td>
<td>23</td>
<td>Myelodysplasia</td>
<td>0</td>
<td>D4</td>
<td>Tracheotomy D18, Dead D33, Limitation of care</td>
</tr>
<tr>
<td>7</td>
<td>33</td>
<td>NIDD</td>
<td>Metformine</td>
<td>D1</td>
<td>Extubated D13 ICU discharge D22</td>
</tr>
<tr>
<td>8</td>
<td>31</td>
<td>Alcohol use disorder</td>
<td>0</td>
<td>D1</td>
<td>ECMO D3 to D13, still intubated at D30</td>
</tr>
<tr>
<td>9</td>
<td>23</td>
<td>Hypertension – COPD – psoriasis</td>
<td>Local dermocorticoid Aspirine Proton pump inhibitor benzodiazepine</td>
<td>D1</td>
<td>Still intubated D18</td>
</tr>
</tbody>
</table>
### Table 1: clinical characteristics, comorbidities, chronic treatment, delay for almitrine testing and outcome. Top: almitrine COVID group; Bottom : “control” COVID group

<table>
<thead>
<tr>
<th>Patient</th>
<th>BMI</th>
<th>Past medical history</th>
<th>Medications</th>
<th>Delay for blood gas after intubation</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>C1</td>
<td>31</td>
<td>Hypertension – COPD</td>
<td>Diuretic – Sartan</td>
<td>D 4</td>
<td>Extubated D14, ICU discharge D18</td>
</tr>
<tr>
<td>C2</td>
<td>29</td>
<td>Testicular carcinoma</td>
<td>0</td>
<td>D1 post intubation</td>
<td>Dead D24, Limitation of care</td>
</tr>
<tr>
<td>C3</td>
<td>30</td>
<td>Breast cancer – obesity - depression</td>
<td>Benzodiazepine</td>
<td>D1 post intubation</td>
<td>Extubated D23, Stepdown care</td>
</tr>
<tr>
<td>C4</td>
<td>25</td>
<td>Hypertension - smoking</td>
<td>NA</td>
<td>D1 post intubation</td>
<td>Extubated D5, ICU discharge D7</td>
</tr>
<tr>
<td>C5</td>
<td>32</td>
<td>NIDD</td>
<td>Proton pump inhibitor Metformine</td>
<td>D1 post intubation</td>
<td>Extubated D18</td>
</tr>
<tr>
<td>C6</td>
<td>28</td>
<td>Hypertension – NIDD –Prostate cancer – asthma</td>
<td>Aspirine – bronchodilator – beta blocker – proton pump inhibitor</td>
<td>D1 post intubation</td>
<td>Death D12, Limitation of care</td>
</tr>
<tr>
<td>C7</td>
<td>30</td>
<td>Hypertension – IDD – COPD</td>
<td>Insulin – sartan – aspirine – statin</td>
<td>D1 post intubation</td>
<td>Extubated at D11, ICU discharge D16</td>
</tr>
</tbody>
</table>

SAS = sleep apnea syndrome; NID = non-insulin-dependent diabetes; ECMO = extra-corporeal membrane oxygenation; COPD = chronic obstructive pulmonary disease; A Fib = atrial fibrillation. ED emergency department.
Table 2: Hemodynamic, pulmonary gas exchange and mechanical ventilation parameters at baseline and after 4 and 12 μg/kg/min of almitrine.

BE = base excess; ScvO2 = central venous O2 saturation; Pra= right atrial pressure; CI = cardiac index; CO = cardiac output; Vt = tidal volume; RR = respiratory rate; PEEP = positive end-expiratory pressure; PIPressure = peak inspiratory pressure; Pplat = plateau pressure.

<table>
<thead>
<tr>
<th>(median (IQR))</th>
<th>Positioning</th>
<th>Baseline</th>
<th>4 µg/kg/min</th>
<th>12 µg/kg/min</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>FiO2 (% condition)</td>
<td>Prone</td>
<td>1.00 (1.00, 1.00)</td>
<td>1.00 (1.00, 1.00)</td>
<td>1.00 (1.00, 1.00)</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>Supine</td>
<td>3 (30.0)</td>
<td>3 (30.0)</td>
<td>3 (30.0)</td>
<td>NA</td>
</tr>
<tr>
<td>PaO2 (mmHg)</td>
<td>Prone</td>
<td>135 (85, 195)</td>
<td>149 (91, 28)</td>
<td>215 (121, 275)</td>
<td>0.06</td>
</tr>
<tr>
<td></td>
<td>Supine</td>
<td>7 (70.0)</td>
<td>7 (70.0)</td>
<td>7 (70.0)</td>
<td>0.06</td>
</tr>
<tr>
<td>PaCO2 (mmHg)</td>
<td>Prone</td>
<td>42 (40, 45)</td>
<td>42.1 (40, 45)</td>
<td>43 (37, 46)</td>
<td>0.45</td>
</tr>
<tr>
<td></td>
<td>Supine</td>
<td>7.38 (7.36, 7.44)</td>
<td>7.40 (7.36, 7.42)</td>
<td>7.41 (7.36, 7.42)</td>
<td>0.71</td>
</tr>
<tr>
<td>pH</td>
<td>Prone</td>
<td>25.1 (23.5, 28.2)</td>
<td>25.3 (24, 27.9)</td>
<td>24.8 (23.9, 27.6)</td>
<td>0.91</td>
</tr>
<tr>
<td></td>
<td>Supine</td>
<td>2.1 (-1.4, 2.7)</td>
<td>1.1 (-0.3, 2.4)</td>
<td>-0.3 (-1.5, 2.5)</td>
<td>0.91</td>
</tr>
<tr>
<td>HCO3 (mmol/L)</td>
<td>Prone</td>
<td>73 (72, 76)</td>
<td>81 (79, 82)</td>
<td>85 (78, 87) *</td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td>Supine</td>
<td>8 (7.9)</td>
<td>9 (8.11)</td>
<td>9 (8.11)</td>
<td>0.03</td>
</tr>
<tr>
<td>Cl (l/min/m²)</td>
<td>Prone</td>
<td>2.1 (1.9, 2.2)</td>
<td>2.2 (1.9, 2.3)</td>
<td>2.2 (1.9, 2.5)</td>
<td>0.33</td>
</tr>
<tr>
<td></td>
<td>Supine</td>
<td>4.2 (3.2, 4.3)</td>
<td>4.1 (3.7, 4.6)</td>
<td>4.3 (4.0, 4.5)</td>
<td>0.42</td>
</tr>
<tr>
<td>CO (l/min)</td>
<td>Prone</td>
<td>23 (22, 24)</td>
<td>24 (22, 25)</td>
<td>24 (22, 25)</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Supine</td>
<td>10 (10, 11)</td>
<td>10 (8, 10)</td>
<td>10 (10, 10)</td>
<td>1</td>
</tr>
<tr>
<td>Vt (ml)</td>
<td>Prone</td>
<td>27 (26, 29)</td>
<td>27 (26, 30)</td>
<td>27 (26, 29)</td>
<td>0.14</td>
</tr>
<tr>
<td></td>
<td>Supine</td>
<td>22 (19, 24)</td>
<td>22 (20, 24)</td>
<td>22 (20, 24)</td>
<td>1</td>
</tr>
</tbody>
</table>
Legends

**Figure 1:** Boxplot representation of the PaO$_2$/FiO$_2$ ratio change in the almitrine group and in the control group between baseline and after treatment measurements (best dose response for patients treated with almitrine and 8-hours after baseline for matched control patients).

*Tukey boxplots show median with 25$^{th}$ and 75$^{th}$ percentiles (lower and upper hinges). Whiskers extend from the correspondent hinge to the largest or smaller value not further than 1.5*interquartile range. Isolated points represent the outlier values.*

**Figure 2:** Individual change of the PaO$_2$/FiO$_2$ ratio (A) and the ScvO$_2$ (B) between baseline and post almitrine administration (best dose response in term of PaO$_2$/FiO$_2$ ratio) in the almitrine group of patients (n=10). Individual change of the PaO$_2$/FiO$_2$ ratio (C) in the matched-control group (n=7) between baseline and H8.

*ScvO$_2$ measurements were not available for the control group.*

*Shape of the individual point corresponds to the position of the patients (circle: prone positioning; triangle: supine positioning).*

*Tukey boxplots on the background show correspondent median with 25$^{th}$ and 75$^{th}$ percentiles (lower and upper hinges). Whiskers extend from the correspondent hinge to the largest or smaller value not further than 1.5*interquartile range.*
Figure 1

![Graph showing P\textsubscript{aO\textsubscript{2}}/F\textsubscript{IO\textsubscript{2}} for Almitrine and Control groups.](image)

- **Groups**: Almitrine, Control
- **Measure**: Baseline, Post measure
- **Statistics**:
  - **p=0.01** between Baseline and Post measure within the Almitrine group.
  - **p=0.9** between Baseline and Post measure within the Control group.
Figure 2

A

B

C

Positioning  ▲ Prone  ▲ Supine

Po2/Fio2

Baseline  Post almitrine administration
(d or 12 µg/kg/min)

Baseline  Post almitrine administration
(d or 12 µg/kg/min)

Baseline  H2 measurement

Almitrine group of patients

Almitrine group of patients

Control group of patients
Authors contributions

MRL: study design, data collection, data interpretation, writing, literature search,

CL: data collection, figures,

MD: data collection, data interpretation

BC : figures, data analysis, data interpretation

JFP: data interpretation, writing, literature search

DP: literature search, study design, data analysis, data interpretation, writing